Please ensure Javascript is enabled for purposes of website accessibility

Why Kura Oncology Stock Is Sliding Today

By Cory Renauer – Nov 24, 2021 at 11:47AM

Key Points

  • Kura Oncology is a clinical-stage oncology company developing experimental cancer drugs.
  • This morning, the company told investors the FDA was putting a phase 1 trial with KO-539, its leukemia treatment, on partial hold.
  • Treatment will continue for patients already enrolled, but there won't be any new enrollments until the agency can assess the risk level.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.

What happened

Shares of Kura Oncology (KURA -1.08%), a clinical-stage biopharmaceutical company, are down sharply in response to a clinical hold for the company's experimental leukemia treatment. The stock was down 15.6% as of 11:20 a.m. ET on Wednesday.

So what 

The Food and Drug Administration placed a partial clinical hold on a phase 1 trial with KO-539 after the death of a patient. The adverse event was potentially associated with differentiation syndrome (DS).

Disappointed investor with face in hands.

Image source: Getty Images.

KO-539 is supposed to treat patients with acute myeloid leukemia by inhibiting a protein called menin. Unfortunately, this isn't the first time a menin inhibitor has been associated with DS, a life-threatening complication of therapy with differentiating agents like KO-539. 

Now what

This is bad news, but not necessarily catastrophic for the company. The FDA halted enrollment of new patients into Kura's dose determination study, but participants who were already enrolled will continue to receive KO-539.

The FDA takes patient safety seriously, even when those patients have an aggressive form of leukemia that relapsed after they received other treatment options. That said, some level of DS risk doesn't necessarily mean KO-539 is all washed up. 

In 2018, the FDA approved Tibsovo, an oral treatment for acute myeloid leukemia that acts differently but is associated with DS. Despite roughly one-fifth of patients exhibiting signs of DS in a pivotal trial, the FDA approved Tibsovo in 2018 with a black box warning for oncologists to monitor for symptoms of the potentially fatal complication. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.